Kunal Pharma Distributors Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.84 Cr
- Company Age 36 Year, 4 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 28.25 Cr
- Revenue Growth 4.56%
- Profit Growth -34.70%
- Ebitda -35.19%
- Net Worth 19.60%
- Total Assets 29.96%
About Kunal Pharma Distributors
Kunal Pharma Distributors Private Limited (KPDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 08 February 1989 and has a history of 36 years. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Kankaria Leasing And Finance Pvt Ltd.. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.84 Cr.
The company currently has active open charges totaling ₹28.25 Cr.
Prahlad Jain, Kunal Jain, and Pramila Jain serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74900TG1989PTC009584
-
Company No.
009584
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Feb 1989
-
Date of AGM
27 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Kunal Pharma Distributors?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunal Jain
|
Director | 30-Sep-2015 | Current |
|
Prahlad Jain
|
Director | 27-Jun-2015 | Current |
|
Pramila Jain
|
Director | 09-Jul-2015 | Current |
Financial Performance of Kunal Pharma Distributors.
Kunal Pharma Distributors Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.56% increase. The company also saw a substantial fall in profitability, with a 34.7% decrease in profit. The company's net worth Soared by an impressive increase of 19.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kunal Pharma Distributors?
In 2023, Kunal Pharma Distributors had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹28.25 Cr
₹0
Charges Breakdown by Lending Institutions
- Citi Bank N.A. : 28.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 May 2017 | Citi Bank N.A. | ₹28.25 Cr | Open |
How Many Employees Work at Kunal Pharma Distributors?
Unlock and access historical data on people associated with Kunal Pharma Distributors, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kunal Pharma Distributors, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kunal Pharma Distributors's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
